Keywords
Gastric cancer is the 5th most common cancer worldwide and is one of the major causes of cancer related deaths [
[1]
]. The COVID-19 pandemic has significantly impacted the provision of cancer care [- Wahed S.
- Chmelo J.
- Navidi M.
- et al.
Delivering esophagogastric cancer care during the COVID-19 pandemic in the United Kingdom: a surgical perspective.
Dis Esophagus. 2020; 33 (doaa091)https://doi.org/10.1093/dote/doaa091
[1]
]. The changes in health system capacity and healthcare-seeking behaviour have lead to severe disruptions in healthcare delivery worldwide causing delayed diagnosis and treatment and, therefore, increasing the risk of adverse outcomes in cancer patients [- Wahed S.
- Chmelo J.
- Navidi M.
- et al.
Delivering esophagogastric cancer care during the COVID-19 pandemic in the United Kingdom: a surgical perspective.
Dis Esophagus. 2020; 33 (doaa091)https://doi.org/10.1093/dote/doaa091
[1]
].- Wahed S.
- Chmelo J.
- Navidi M.
- et al.
Delivering esophagogastric cancer care during the COVID-19 pandemic in the United Kingdom: a surgical perspective.
Dis Esophagus. 2020; 33 (doaa091)https://doi.org/10.1093/dote/doaa091
The Upper Gastrointestinal Surgical Society (TUGSS), through its Global Level of Harm Project (GLEOHUG) conducted a survey-based study with the participation of 145 centers from 50 countries around the world. This study showed that during the first year of the pandemic the management of gastric cancer patients was globally affected by decreasing the frequency of multidisciplinary team meetings (43,4%) and the number of elective gastrectomies (54,5%). Moreover, there was a higher clinical stage migration (29,0%), a higher metastatic disease rate (33,8%), an increased need of definitive palliative treatment (26,9%), patients' frailty (21,4%), waiting list times (52,4%), the number of urgent (26,9%) and palliative surgeries (16,6%), overall complication rates (16,6%), Clavien-Dindo 3 or higher complications (13,1%), leak rate (7,5%) and pulmonary infections (26,9%). Besides this, there was a high rate of postoperative COVID-19 infection (43,8%) and associated mortality (18,7%).
The COVID-19 pandemic has put cancer patients at risk of adverse outcomes due to delays in diagnosis and treatment [
[2]
]. Experienced multidisciplinary teams have had a critical role in tailoring management in order to ensure oncological outcomes and quality of life for these patients [[1]
]. While in high-income countries gastric cancer surgical treatment could be safely delayed provided that neoadjuvant treatment (NAT) was administered [- Wahed S.
- Chmelo J.
- Navidi M.
- et al.
Delivering esophagogastric cancer care during the COVID-19 pandemic in the United Kingdom: a surgical perspective.
Dis Esophagus. 2020; 33 (doaa091)https://doi.org/10.1093/dote/doaa091
[1]
], in low-medium-income countries where patients could not receive neither NAT nor surgery, these delays could lead to increased recurrence rates and excess mortality [- Wahed S.
- Chmelo J.
- Navidi M.
- et al.
Delivering esophagogastric cancer care during the COVID-19 pandemic in the United Kingdom: a surgical perspective.
Dis Esophagus. 2020; 33 (doaa091)https://doi.org/10.1093/dote/doaa091
[2]
]. Furthermore, those patients who underwent surgery were prone to have a decreased compliance with ERAS protocols, higher complication rates and mortality, especially those who underwent urgent procedures or developed postoperative COVID-19 infection. Additionally, the hospital work overload may have made rescue from postoperative complications difficult, increasing the severity of complications and the mortality rate [[3]
].One may think that the worst part of the COVID-19 pandemic and its effects were limited to its first year. However, in the case of cancer patients, the effects of the pandemic can go beyond its duration. A Canadian study [
[4]
] showed that cancer care disruptions would lead to an essential increase in cancer mortality with the highest excess expected for 2022. Therefore, it is extremely important that cancer pathways are strengthened and patients' prioritization improved in order to reduce avoidable deaths before future severe care disruptions emerge [[3]
].Acknowledgements
The authors of the present work would like to thank all participants in the survey for their efforts and commitment during the COVID-19 pandemic. Special thanks to Professor Kamal Mahawar and The Upper Gastrointestinal Surgical Society (TUGSS); Professor Domenico D'Ugo and the European Society of Surgical Oncology's (ESSO) Board of Directors; Dr. Andreas Brandl, Dr. Wim Ceelen, and the ESSO-European Young Surgeons and Alumni Club (EYSAC) Research Academy for their support and distribution of the survey.
References
- Delivering esophagogastric cancer care during the COVID-19 pandemic in the United Kingdom: a surgical perspective.Dis Esophagus. 2020; 33 (doaa091)https://doi.org/10.1093/dote/doaa091
- Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.Lancet Oncol. 2021 Nov; 22 (Epub 2021 Oct 5): 1507-1517https://doi.org/10.1016/S1470-245(21)00493-9
Osorio J, Madrazo Z, Videla S, et al. Analysis of outcomes of emergency general and gastrointestinal surgery during the COVID-19 pandemic.
- Predicted long-term Impact of COVID-19 pandemic-related care delays on cancer mortality in Canada.Int J Cancer. 2022; 150: 1244-1254
Article info
Publication history
Published online: March 01, 2023
Accepted:
February 25,
2023
Received:
February 22,
2023
Identification
Copyright
© 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
